BIOMAT Database Logo BIOMAT Database Logo

The role of noradrenaline and selective noradrenaline reuptake inhibition in depression. 2002

N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Department of Pharmaceutical Sciences, University of Modena and Reggio Emilia, Modena, Italy. brunello.nicoletta@unimo.it

Depression is a common disorder that impacts on all aspects of a person's life. For the past 10 years, clinicians have focused on serotonin in their treatment of depression. This is largely due to the growing acceptance of the efficacy and safety of the selective serotonin reuptake inhibitors (SSRIs) in comparison with older tricyclic antidepressants (TCAs). However, evidence for a role of noradrenaline in depression has been accumulating for some time, beginning with the discovery that drugs which either caused or alleviated depression acted to alter noradrenaline metabolism. Until recently, the role of noradrenaline in depression was predicted from clinical experience with noradrenergic TCAs (desipramine, nortriptyline and protriptyline) and selective serotonin and noradrenaline reuptake inhibitors (venlafaxine, milnacipran). The licensing of reboxetine, a selective noradrenaline reuptake inhibitor now allows the role of noradrenaline in depression to be investigated directly. This review presents key data from the literature that support a role for noradrenaline in depression taking into account neurophysiology, psychopharmacology and clinical trial data.

UI MeSH Term Description Entries
D007099 Imipramine The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group. Imidobenzyle,Imizin,4,4'-Methylenebis(3-hydroxy-2-naphthoic acid)-3-(10,11-dihydro-5H-dibenzo(b,f)azepin-5-yl)-N,N-dimethyl-1-propanamine (1:2),Imipramine Hydrochloride,Imipramine Monohydrochloride,Imipramine Pamoate,Janimine,Melipramine,Norchlorimipramine,Pryleugan,Tofranil
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D009638 Norepinephrine Precursor of epinephrine that is secreted by the ADRENAL MEDULLA and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers, and of the diffuse projection system in the brain that arises from the LOCUS CERULEUS. It is also found in plants and is used pharmacologically as a sympathomimetic. Levarterenol,Levonorepinephrine,Noradrenaline,Arterenol,Levonor,Levophed,Levophed Bitartrate,Noradrenaline Bitartrate,Noradrénaline tartrate renaudin,Norepinephrin d-Tartrate (1:1),Norepinephrine Bitartrate,Norepinephrine Hydrochloride,Norepinephrine Hydrochloride, (+)-Isomer,Norepinephrine Hydrochloride, (+,-)-Isomer,Norepinephrine d-Tartrate (1:1),Norepinephrine l-Tartrate (1:1),Norepinephrine l-Tartrate (1:1), (+,-)-Isomer,Norepinephrine l-Tartrate (1:1), Monohydrate,Norepinephrine l-Tartrate (1:1), Monohydrate, (+)-Isomer,Norepinephrine l-Tartrate (1:2),Norepinephrine l-Tartrate, (+)-Isomer,Norepinephrine, (+)-Isomer,Norepinephrine, (+,-)-Isomer
D011941 Receptors, Adrenergic Cell-surface proteins that bind epinephrine and/or norepinephrine with high affinity and trigger intracellular changes. The two major classes of adrenergic receptors, alpha and beta, were originally discriminated based on their cellular actions but now are distinguished by their relative affinity for characteristic synthetic ligands. Adrenergic receptors may also be classified according to the subtypes of G-proteins with which they bind; this scheme does not respect the alpha-beta distinction. Adrenergic Receptors,Adrenoceptor,Adrenoceptors,Norepinephrine Receptor,Receptors, Epinephrine,Receptors, Norepinephrine,Adrenergic Receptor,Epinephrine Receptors,Norepinephrine Receptors,Receptor, Adrenergic,Receptor, Norepinephrine
D002394 Catechol O-Methyltransferase Enzyme that catalyzes the movement of a methyl group from S-adenosylmethionone to a catechol or a catecholamine. Catechol Methyltransferase,Catechol-O-Methyltransferase,Catechol O Methyltransferase,Methyltransferase, Catechol,O-Methyltransferase, Catechol
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077593 Reboxetine A morpholine derivative that is a selective and potent noradrenaline reuptake inhibitor; it is used in the treatment of DEPRESSIVE DISORDER. 2-((2-Ethoxyphenoxy)benzyl)morpholine methanesulfonate,Reboxetine Mesylate,Vestra
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Reversal of tetrabenazine induced depression by selective noradrenaline (norepinephrine) reuptake inhibition.
October 1999, Journal of neurology, neurosurgery, and psychiatry,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Reboxetine, a selective noradrenaline reuptake inhibitor for the treatment of depression.
September 1999, Drugs of today (Barcelona, Spain : 1998),
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
[Selective serotonin and noradrenaline reuptake inhibitors: a step forward in the treatment of depression?].
January 2005, MMW Fortschritte der Medizin,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials.
August 2013, Journal of psychopharmacology (Oxford, England),
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Predicting response: noradrenaline reuptake inhibition.
May 1999, International clinical psychopharmacology,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
[Selective noradrenaline-dopamine reuptake inhibition (SNDRI). More latitude for antidepressive therapy].
May 2007, MMW Fortschritte der Medizin,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Selective noradrenaline reuptake inhibitors for schizophrenia.
January 2018, The Cochrane database of systematic reviews,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Selective noradrenaline reuptake inhibition enhances serotonergic neuronal activity and transmitter release in the rat forebrain.
February 2004, Journal of neural transmission (Vienna, Austria : 1996),
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
Synergistic benefits of serotonin and noradrenaline reuptake inhibition.
January 1998, Depression and anxiety,
N Brunello, and J Mendlewicz, and S Kasper, and B Leonard, and S Montgomery, and J Nelson, and E Paykel, and M Versiani, and G Racagni
[Analgesic effect of the selective noradrenaline reuptake inhibitor reboxetine].
February 2002, Der Nervenarzt,
Copied contents to your clipboard!